SEC Form 4 · accession 0001628280-26-044419
Crinetics Pharmaceuticals, Inc. · CRNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephanie Okey
Director
Period of report
Jun 17, 2026
Accepted (ET)
Jun 18, 2026 · 5:23 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001658247
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 17, 2026 | S | 6,292 | $35.62 | D | 7,008 | D | |
| Common StockF1,F3 | Jun 17, 2026 | S | 608 | $36.22 | D | 6,400 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025.
- F2The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $35.62 per share. The range of sale prices on the transaction date was $35.19 to $36.06. Detailed information on the exact number of shares can be obtained from the Issuer upon request.
- F3The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $36.22 per share. The range of sale prices on the transaction date was $36.19 to $36.29. Detailed information on the exact number of shares can be obtained from the Issuer upon request.